Simplex Trading’s Verve Therapeutics VERV Stock Holding History

Simplex Trading’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-81,129	Closed	-$911K	–	10158
2025 Q2	$911K	Buy	81,129 +68,549	+545%	+$391K	﹤0.01%	2871
2025 Q1	$57K	Buy	12,580 +10,349	+464%	+$69.3K	﹤0.01%	5636
2024 Q4	$12K	Sell	2,231 -16,846	-88%	-$95K	﹤0.01%	7096
2024 Q3	$92K	Sell	19,077 -8,394	-31%	-$48.8K	﹤0.01%	5320
2024 Q2	$134K	Buy	27,471 +18,256	+198%	+$115K	﹤0.01%	5057
2024 Q1	$122K	Buy	+9,215	New	+$122K	﹤0.01%	5385
2023 Q3	–	Sell	-324	Closed	-$5.22K	–	9918
2023 Q2	$6K	Buy	+324	New	+$5.4K	﹤0.01%	7847
2022 Q3	–	Sell	-173	Closed	-$5.52K	–	10958
2022 Q2	$2K	Sell	173 -3,039	-95%	-$47.1K	﹤0.01%	9430
2022 Q1	$73K	Buy	3,212 +3,152	+5,253%	+$90.1K	﹤0.01%	6603
2021 Q4	$2K	Buy	+60	New	+$2.52K	﹤0.01%	10072

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Simplex Trading's VERV Position: Q3 2025 in Review

Simplex Trading sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 81,129 shares — an estimated $911K sold.

Simplex Trading first reported a position in VERV in Q4 2021 and held it in 10 quarters. The position peaked at $911K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Simplex Trading reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Simplex Trading sold 81,129 Verve Therapeutics shares in Q3 2025, an estimated $911K.
Simplex Trading first reported a position in Verve Therapeutics in Q4 2021 and held it in 10 quarters.
Simplex Trading's Verve Therapeutics position peaked at $911K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.